Korro Bio, Inc.
KRRO· Nasdaq
KRROKorro Bio, Inc.
Filed Nov 16, 2020 · 10-Q · 47 days after period end · 0001564590-20-054017
| Metric | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|
| Revenue | $11.25M | $24.24M | — |
| Net Income | -$5.34M | -$575.00K | -$5.14M |
| EPS Diluted | -$0.16 | -$0.73 | -$3.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
ended Sep 30, 2020 · filed Nov 16, 2020 · 47 d after period end
